The epigenetic regulation of the opioid system: New individualized prompt prevention and treatment strategies.

Authors and Affiliations

Iraia Muñoa, Itziar Urizar, Luis Casis, Jon Irazusta, Nerea Subiran*

Department of Physiology Faculty of Medicine and Dentistry, University of the Basque Country, Leioa, Bizkaia, Spain.

Contact

Nerea Subirán. Department of Physiology. Faculty of Medicine and Dentistry, University of the Basque Country

E-mail: nerea.subiran@ehu.es

Telephone: +34 94 601 5673

Fax: +34 94 601 5662,

This is the peer reviewed version of the following article: Muñoa, I., Urizar, I., Casis, L., Irazusta, J. and Subirán, N. (2015), *The Epigenetic Regulation of the Opioid System: New Individualized Prompt Prevention and Treatment Strategies*. **J. Cell. Biochem.,** 116: 2419-2426. , which has been published in final form at https://doi.org/10.1002/jcb.25222. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley's version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.

Abstract

The most well-known physiological effect associated with opiod system is their efficacy in pain reduction or analgesia, although their effect on a variety of other physiological and physiophological functions has become apparent in recent years. This review is an attempt to clarify in more detail the epigenetic regulation of opioid system to understand with more precision their transcriptional and posttranscriptional regulation in multiple pyisiological and pharmacological contexts. The opioid receptors show an epigenetic regulation and opioid peptide precursors by methylation, chromatin remodeling and microRNA. Although the opioid receptor promoters have similarity between them, they use different epigenetic regulation forms and they exhibit different pattern of expression during the cell differentiation. DNA methylation is also confirmed in opioid peptide precursors, being important for gene expression and tissue specificity. Understanding the epigenetic basis of those physiological and physiopathological procesess is essential for the development of individualized prompt prevention and treatment strategies.

Keywords

Epigenetic, methylation, chromating remodeling, miRNA, opioids, drug addiction.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

36 # Introduction

37 The opioid system is a biological communication system for which activity is mediated by the 38 so-called endogenous opioid peptides (EOPs). Pharmacologically, it has been described three 39 opioid receptors (ORs): mu opioid receptor (MOR), delta opioid receptor (DOR) and kappa 40 opioid receptor (KOR), which belong to the 7-transmembrane, G protein-coupled receptors 41 super-family (Law, et al., 2004). Later it was discovered the fourth OR, the nociceptin receptor 42 (NOP). The comparison of the amino acid sequence and nucleotides has established that four 43 genes are highly conserved in their homolog codificant exons (73-100%), which are located in 44 the middle of each gene. That exon codifies the 7-transmembrane domain, suggesting that 45 four ORs come from the same ancestor gene. Also it has a single intron in the coding region. 46 However, the four ORs diverge in their amino-end which is produced out from the cellular 47 surface, and also in the carboxyl-end which is extended in the intracellular space (9-20% of 48 conservation) (Neer, 1995). Those slight differences explain specificity between the ligand 49 union pattern, pharmacological effects and transduction signaling pathway of each OR 50 (LaForge, et al., 2000). But, despite their conserved structure, it has been proved that each 51 gene has a single regulatory pathway and shows a different expression pattern (Wei and Loh, 52 2002). These genes are *Oprm1*, *Oprd1*, *Oprk1* and *Oprl1*. cDNA alignment studies with the 53 genomic DNA and mRNA processing have established the existence of several isoforms or 54 variants produced by each OR, by means of the use of alternative splicing, alternative 55 promoters (*Oprm1*, *Oprk1*), alternative polyadenylation sites (*Oprk1*) or inclusions in non- 56 coding exons (Wei and Loh, 2002).

57 The endogenous opioid peptides, endorphins, enkephalins, dynorphins and 58 orphanin/nociceptins, are derived from precursors encoded by proopiomelanocortin (POMC), 59 proenkephalin (PENK), prodynorphin (PDYN) and nociceptin/orphanin FQ (PNOC), respectively 60 (LaForge, et al., 2000, Levran, et al., 2012). However, biological approaches have demonstrated

that in mammals, these peptides are grouped in three major types of opioid peptides: endorphins, enkephalins and dynorphins (Koneru A, Satyanarayana S and Rizwan S., 2009). Recent studies have shown that there are more endogenous opioid peptides which do not belong to these three major types and which precursors are not yet known. These two endogenous opioid peptides are tetrapeptides, endomorphin-1 (Tyr-Pro-Tr p-Phe-Nh2) and endomorphin-2 (Tyr-Pro-Phe-Phe-NH2) (Fichna, et al., 2007). Although their better known function of the endogenous opioid peptides is to suppress pain (analgesia), currently other different physiological functions have been reported. The system is involved in brain development, regeneration and plasticity phenomena, taking part even in higher functions as memory and learning; sensory functions regulation; production of changes in eating behavior; modulation of mental illnesses such as anxiety or depression and mood; in gastrointestinal, renal and hepatic functions; modulation of cardiovascular response and blood pressure; modulation of breathing, causing deficiencies in respiratory and thermoregulatory responses; modulation of immunologial response, particularly immune-suppression; regulating the movement and general activity; and finally in the regulation of reproductive function(Bodnar, 2007, Subiran, et al., 2011). This review tries to on clarify the epigenetic mechanisms of opioid system, focusing more detail on methylation patterns, chromatin remodeling and microRNA regulation to understand with more precision their transcriptional and posttranscriptional regulation in multiple physiological and pharmacological contexts.

The epigenetic Regulation of Opioid Receptors

Four ORs are subjected to epigenetic regulation since they maintain several features, making them susceptible to be controlled by this machinery: all of the genes are rich in CpG islands

1
2
3 85 and hence, they can be highly methylated, their promoters show several types of
4
5 86 modifications in different cellular stages or culture conditions, and chromatin remodeling
6
7 87 occurs in their promoters producing changes in their expression patterns in the differentiation
8
9 88 process (LaForge, et al., 2000).

	OPRM1	OPRD1	OPRK1	OPRL1
Silencing				
Regulatory elements	Oct1, PU.1, PARP1, Sp3, REST	Sp3, IK	IK	-
Metilation Mechanisems	Metilation ↑ MeCp2	Metilation ↑ MeCP2	-	-
Histon modifications	-	Histone deacetilases H3, H4	H3K9 me2	-
MiroRNA	miR-23b, miR-339, Let-7	-	-	-
Activation				
Regulatory elements	Sox2, Sp1, iGA, PCBP, CREB,	STAT6, Sp1, Ets-1, USF, NF-kB, AP2	c.Myc, Sp1, AP2	
Metilation Mechanisems	Hipometilation ↓ MeCp2	Hipometilation ↓ MeCp2	-	Hipometilation
Histon modifications	Histone acetilases H3, H4	Demetilation of H3K9me3 by NGF/PI3K signalling	H3K4 me2	-
MiroRNA	-	-	-	-

89

90 Mu opioid receptor (*Oprm1)*

91 MOR is codified by the gene *Oprm1*, which has an important role in clinical effects of opiates,

92 such as analgesia, tolerance development, and physical dependency under long drug

93 treatment. MOR is one of the four ORs receiving further action by endogenous opioids, opiates

94 and opioid analgesic drugs and also by exogenous opioid drugs as follows methadone, heroin

95 and morphine (Kreek, et al., 2002). Certain numbers of splicing variants have been named,

96 they are variants of the MOR mRNA which are modified in their 5'UTRs and are differentially

97 regulated at transduction level (Song, et al., 2009). This receptor uses two closely positioned

98 promoters, the distal promoter and the proximal promoter, which is responsible for most of

99 the activity of the gene. Both of them belong to TATA-less type promoter, which are rich in CGs

and they have several regulatory elements. Lots of transcription factors have been examined as transcription regulators of the activity of *Oprm1*: Sox2 activators (Sry-like high-mobility-group box gene), Sp1 (specificity protein 1), iGA (Sp1 on an inverted GA motif), PCBP (poly C binding protein) and CREB (cyclic adenosine monophosphate response element binding protein). In contrast, the repressors are, Oct-1 (octamer-1), PU.1 (PU box binding on a 34-bp silencer region), PARP1 (polyADP-ribose polymerase 1 on a double-stranded poly-C sequence), Sp3 (two TFs binding to the 5’ UTR specificity protein 3) and REST (repressor element-1 silencing transcription factor) (Hwang, et al., 2009, Wei and Loh, 2011).

The *Oprm1* promoter is heavily methylated in the CpG islands, in the undifferentiated embryonic carcinoma cells, thus the *Oprm1* is silenced. The silenced *Oprm1* can be activated in two ways, the first one by decreasing the expression of the methyl CpG binding protein 2 (MeCP2) and the second one by adding a histone acetylation inducer, that is the trichostatin A (TSA) (Lin, et al., 2008). In addition, DNA methylation on the *Oprm1* can be reduced adding an artificial demethyilation agent such as the 5’-Aza-2’-deoxycytidine (5-Aza-C), but it is not clear which type of endogenous signal triggers the DNA demethylation on the promoter of undifferentiated cells.

Other studies further provided that a higher-order chromatin conformational remodeling of the *Oprm1* promoter occurs during neuronal differentiation in embryonic carcinoma cells (Hwang, et al., 2010). Together with the silencing of *Oprm1* in pre-differentiated cultures, the promoter region is also organized into an ordered nucleosome. Whereas neuronal differentiation occurs by the retinoic acid (RA) induction, nucleosomes of the promoter region change their positions, and they start to recruit specific chromatin remodelers, which remodel the promoter and activate the gene. In that way, the activation or silencing of *Oprm1* is correlated with histone modification, as in brain studies is observed, that to achieve *Oprm1* activation, it is necessary the hyperacethylation of H3 and H4 (Song, et al., 2009).

Recent studies have demonstrated that in term of non coding RNA, there are some miRNA linked with epigenetic regulation: miR-23b, miR-339 and Let-7 miR. On the one hand, miR-23b interacts with the 3'UTR of *Oprm1* through the K box motif (5'-UGUGAU-3'), which is a conserved sequence. That interaction blocks the attachment between *Oprm1* mRNA and the polysomes, hence, the transduction is arrested and MOR expression is canceled at protein level (Wu, et al., 2013). On the other hand, the binding of miR-339 with *Oprm1* in the 3'UTR, suppress the receptor expression which is recovered after the addition of miR-339 inhibitor or mutating the binding target (Hwang, et al., 2012). Finally, the last miRNA discovered in *Oprm1* regulation is Let-7 miR, which also regulates opioid tolerance. Let-7 miR binds to its target in the *Oprm1* 3'UTR and represses its expression, sequestering *Oprm1* mRNA to P-bodies and finally leading to translational repression. Thus, binding between *Oprm1* transcript and polysomes is decreased in a Let-7 dependent way (He, et al., 2010). (Table 1)

Delta opioid receptor (*Oprd1*)

DOR, which is codified by the gene *Oprd1*, is involved in the modulation of addition, affective state, pain perception and analgesia. It has a single promoter, TATA-less and is rich in CGs and although some studies have shown that *Oprd1* initiates its transcription in two adjacent sites since there is no study which confirms that alternative splicing (Wang, et al., 2003). Studies of transcriptional regulation of DOR have focused on activating factors, such as, STAT6, Ik (Ikaros), Sp1/Sp3, Ets-1 (E-twenty six 1), USF (upstream stimulatori factor), NF-kB, and AP2 (Wei and Loh, 2011, Wang, et al., 2003).

In studies using embryonic carcinoma cells, the *Oprd1* is constitutively active in undifferentiated cells, but it becomes inactive in the neuronal differentiation (Wang, et al., 2003). It has been shown a heavy DNA methylation on *Oprd1* promoter in neural crest-derived cells, where it is not expressed and a demethylation in neuroblastoma cells, where *Oprd1* gene is highly expressed, displaying an inverse correlation between both cell types. In addition, 5-

Aza-C treatment on the culture generates an increased *Oprd1* expression in neural crest-derived cells (Wang, et al., 2005).

Through different studies, scientists have been trying to establish a connection between promoter's methylation state and chromatin modifications, concluding that, this connection is important to regulate *Oprd1* expression. In lack of methylation, *Oprd1* promoter in neuroblastoma cells maintains its accessibility if comparing with partially methylated *Oprd1* promoter in neural crest-derived cells (Wang, et al., 2005). It suggests that the silencing induced by the methylation generates a modification in the chromatin structure limiting the accessibility to the promoter during the transcription. For example, *Oprd1* promoter methylation contributes to MeCP2. In consequence, the histone deacetylase can access to the chromatin, generate decreased levels of H3 and H4 acetylation in *Oprd1* promoter region and change the chromatin structure. In contrast, when *Oprd1* promoter is completely methylated, it is correlated with low acetylation level in H3 (Wang, et al., 2005). Furthermore, other studies show the signaling role of fosfatidilinositol 3-kinase (PI3K) in the regulation of H3K9 state during neuronal differentiation induced by the nerve growth factor (NGF). That is to say, NGF/PI3K signaling is involved in demethylase activity of H3K9me3 in rat adrenal pheochromocytoa cells changing from a chromatin repressive mark to a activating mark (Chen, et al., 2008). (Table 1)

Kappa opioid receptor (*Oprk1*)

KOR is codified by *Oprk1*, and has an important role in a wide range of physiological systems, such as, pain regulation, drug abuse addiction, neuroendocrine regulation, cardiovascular functions, breathing, temperature regulation, nourishment behavior and ability in stress response (Bruchas, et al., 2010, Knoll and Carlezon, 2010). This OR also modulates the effect of opiates, cocaine and other drugs, through the modulation of the basal level and dopaminergic tone induced by drugs (Knoll and Carlezon, 2010). Several alternative splicing variants have

1
2
3 175 been named, some of them are disturbed in the 5'UTR of *Oprk1* mRNA and they are
4
5 176 differentially regulated at transduction level; others are disrupted in the 3'UTR and they are
6
7 177 differentially regulated at stability level or RNA transport (Hu, et al., 2002). In different studies,
8
9 178 at least six mRNA variants have been validated and they are generated from the same gene
10
11 179 but through the use of two alternative promoters (P1 and P2, TATA-less and rich in GCs) and
12
13 180 two alternative polyadenylation sites, besides the inclusion of one non codifying exon
14
15 181 (upstream), where the alternative splicing occurs to produce different 5'UTRs (Lu, et al., 1997).
16
17 182 The transcription factors which regulate this gene include three positives, the proto-oncogene
18
19 183 c-Myc, Sp1 and activating protein (AP2) and one negative, Ikaros (IK) (Wei and Loh, 2011).
20
21
22
23 184 *Oprk1* is constitutively active and highly expressed in embryonic carcinoma cells in proliferative
24
25 185 state, and once the cells complete that differentiation induced by RA, *Oprk1* expression
26
27 186 decreases. Because there is no evidence on charges in methylation pattern, it has been
28
29 187 suggested that the acquisition of chromatin repressive marks is the main epigenetic regulator
30
31 188 of *Oprk1* expression (Chen, et al., 1999, Bi, et al., 2001). In proliferative embryonic carcinoma
32
33 189 cells that are in differentiation, the P1 promoter of *Oprk1* has a totally accessible chromatin
34
35 190 conformation, while, the promoter P2 shows a totally inaccessible chromatin (Lu, et al., 1997).
36
37 191 The transcription factors, such as, Sp1 can bind promoter P1 and activate transcription.
38
39 192 However, after embryonic carcinoma cell differentiation, the chromatin structure gets ordered
40
41 193 and organized, and in that way Sp1 loses the possibility to bind (Park, et al., 2005). Studies
42
43 194 using the embryonic carcinoma cells have revealed a biphasic pattern, which shows that *Oprk1*
44
45 195 expression is stated again later in differentiated cell populations. This reactivation is explained
46
47 196 through the action of transcription factor NGF, because differentiated cells start to express
48
49 197 NGF-binding receptors. The NGF binding transmits signals to activate AP2 transcription factor
50
51 198 to bind this latter to P2 promoter, inducing changes in the *Oprk1* promoter epigenetic marks
52
53 199 from silenced H3-K9-me2 to activated H3-K4-me2 (Park, et al., 2008). (Table 1)
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

200 # Nociceptin receptor (*Oprl1*)

201 NOP, which is encoded by opioid receptor like 1 gene (*Oprl1*), is a G-protein coupled receptor
202 with high homology to opioid receptors *Oprm1, Oprd1* and *Oprk1* (Mollereau, et al., 1994,
203 Wick, et al., 1995). It shares many structural traits with other OR genes, especially in terms of
204 primary structure (60% homology), yet its pharmacological profile in not opioid. Anatomic data
205 reveal that the *Oprl1* receptor is widely expressed in the brain, spinal cord, and peripheral
206 nervous system, and is found in areas involved in various processes: pain and sensory
207 perception, memory, stress, motricity and hormonal regulation (Mollereau, et al., 1994). *Oprl1*
208 mRNA is expressed as two alternatively spliced forms, which differ only in their 5'UTRs (Wick,
209 et al., 1995). It consists of five exons with a TATA-box in its 5' flanking region, and the protein
210 coding region starts in exon 2 and ends in exon 4.

211 Regarding epigenetic regulation, it is the less studied receptor. A recent study on
212 environmentally regulated gene expression shows, that *Oprl1* gene together with other
213 candidate genes is epigenetically regulated by the methylation of CpG islands (Zhang, et al.,
214 2013a). It reports a hypermethyation in the CpGs of the *Oprl1* gene, and an elevated overall
215 methylation levels in the promoter region too, in a changing environment exposure, leading to
216 changes in gene transcription and an increased risk for other disorders (Zhang, et al., 2013a).

217 Others have worked with different epigenetic modifications, as histone methylation,
218 highlighting that the reduction of mRNA levels of the *Oprl1* gene are supported by the
219 decrease of H3K4me3 and the increase of H3K27me3, it is said, a decreased level of the
220 activating marker and the increased level of the repressive mark (Caputi, et al., 2014). To the
221 date, there is no evidence of research in miRNA regulation of this gene. (Table 1)

222 **Table 1: The epigenetic mechanisems involved in the Opioid Receptors gene expression**

223

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

224 # The epigenetic Regulation of Opioid Protein
225 # Precursors

226 The endogenous opioid peptides are derived from precursors encoded by POMC, PENK, PDYN
227 and PNOC (Tseung, 1995). The importance of the peptide processing enzymes is evident from
228 studies examining the forms of the opioid peptides in different tissues, because each one has
229 different bioactive properties (Tseung, 1995).

	POMC	PENK	PDYN	PNOC
Silencing				
Regulatory elements	nGRE	-	DREAM	-
Metilation Mechanisems	Metilation ↑MeCp2	Metilation ↑MeCp2	Metilation ↑MeCp2	Metilation
Histon modifications		H3K9 me2	H3K27me3	H3K27me3
MiroRNA	miR-375	miR-29c	-	-
Activation				
Regulatory elements	FoxO1, STAT3 Sp1, NF-kB	AP2, Sp1, CREB	AP1	CREB, NF-kB
Metilation Mechanisems	Hipometilation		H3K4me3, H3K9ac	H3K9ac
Histon modifications	H3K9ac	H3K4 me3	-	-
MiroRNA	-	-	-	-

230

231 ## Proopiomelanocortin gene (*POMC*)

232 The pro-opiomelanocortin (*Pomc)* gen, encodes a cDNA spanning 3 exons and 2 introns. The
233 sequence covers four activating transcription factor binding sites (FoxO1, STAT3, Sp1, NF-κB)
234 and one inhibiting transcription factor binding site (nGRE) (Plagemann, et al., 2009). *Pomc* is a
235 precursor polypeptide, which is cleaved in a tissue specific fashion by prohormone convertases
236 to yield a variety of bio-active peptides, including α-melanocortin stimulating hormone (α-
237 MSH), β-lipotropin (β-LPH), β-endorphin and adrenocorticotropin (ACTH), these two latter, are

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

238 the principal components of the hypothalamic-pituitary-adrenal axis. β-endorphin and met-
239 enkephalin are created from β-LPH and they both are the most powerful opioids. These
240 peptides play diverse roles in pathophysiology, including obesity, depression, skin
241 pigmentation, adrenal development and regulation of the HPA axis. In other tissues, including
242 the hypothalamus, placenta and epithelium, all potential cleavage sites may be used to
243 produce peptides responsible for energy homeostasis, pain, perception, melanocyte
244 stimulation and immune responses. *Pomc*-derived peptides actively regulate drug-related
245 behaviors (Levran, et al., 2012, O'Malley, et al., 2002).

246 It has been suggested that there is a variable tissue specific CpG island mehtylation, and that it
247 has important implications for gene expression. Some studies revealed 2 CpG islands within
248 the mouse *Pomc* gene locus (Gardiner-Garden and Frommer, 1994). The called CpG island 1,
249 flanking the *Pomc* transcription start site, which is highly tissue-restricted, and the CpG island
250 2, approximately 5 kb downstream, comprising the third exon of the *Pomc* gene, which is
251 weakly active in many tissues (Lavender, et al., 1991). In ACTH-secreting tumors and *Pomc*
252 expressing cell lines, *Pomc* is unmethylated at the pituitary-specific promoter region. In
253 contrast, in non-ACTH-secretion tumors, this region is heavily methylated. In addition, *Pomc* is
254 heavily methylated at the same region in a number of normal ACTH-non-expressing tissues
255 including: pancreas, spleen, lung, testes and peripheral blood leukocytes (Lavender, et al.,
256 1991). Moreover, studies in rodents have shown that *Pomc* DNA methylation can be altered by
257 environmental conditions. For example, in a neonatal model of obesity, the hypothalamus
258 revealed hypermethylation of CpG dinucleotides in the *Pomc* promoter, and stressor factors
259 elevate *Pomc* mRNA levels in the pituitary (Wu, 2012). The DNA methylation appears to be
260 responsible for controlling *Pomc* gene expression by recruiting MeCP2 to silence the gene.
261 MeCP2 is phosphorylated at serine 438 and generates dissociation from the *Pomc* promoter.
262 As a result of that, the lack of MeCP2 prevent the binding of co-repressor complex such as
263 histone deacetylase 2 (Hdac2) and DNA (cytosine-5)-methyltransferase 1(Dnmt1) at the

promoter losing the capacity to maintain of DNA methylation pattern during cell replication (Wu, 2012).

On the other hand, other epigenetic mechanism seems to increase H3K9 acetylation levels in late-gestation ewe fetal hypothalami, although it shows no change in the expression of *Pomc* mRNA (Stevens, et al., 2010). Some studies have been carried out on beta-endorphin that reduces its production in POMC neurons, by decreasing levels of activation histone marks H3K4, aceH3K9 and pH3S10 and increasing the levels of the repressive histone mark H3K9 (Bekdash RA, 2012).

In the case of non coding RNA regulation, different studies have demonstrated that miR-375 dramatically inhibits *Pomc* expression both at the gene and protein levels by targeting mitogen activated protein kinase 2 (MAP2K8) and mediating the Corticotropin releasing factor signaling pathway in AtT-20 cells (Zhang, et al., 2013b). Finally, a recent study has highlighted, that Dicer-derived miRNAs are essential for survival and maintenance of *Pomc* expressing neurons during post-natal and early adulthood, suggesting that the deletion of Dicer controls *Pomc* gene expression (Schneeberger, et al., 2012). (Table 2)

Proenkephalin gene (*PENK*)

PENK is a large precursor, which is processed through the action of proprotein convertase 1 (PC1) and proprotein convertase 2 (PC2) to produce several peptide sequences: 4 met-enkephalin copies and 1 leu-enkephalin, met-enkephalin-Arg^6-Phe^7, met-enkephalin-Arg^6-Gly^2-Leu^8, sin enkephalin copy and C- or N- terminally extended variants of these peptides(Goumon, et al., 2000). The gene consists of four exons separated by three introns, and there are also identificated several repetitive DNA sequences within and flanking the gene. PENK-derived peptides act on MOR and DOR to produce rewarding actions of substances of abuse in different brain regions, including the ventral tegmental area and nucleus accumbens (NAc) (Levran, et al., 2012). They are also involved in analgesia, responses to stress and pain

and regulation of appetite and sleep (Kieffer and Gaveriaux-Ruff, 2002). The structural organization of the *Penk* gene exhibits similarities to the organization of the *Pomc* gene suggesting that two opioid peptide precursors may have arisen by duplication from a common ancestral gene.

Data shows that *Penk* expression is specific for cell-type and tissue-compartment and that this expression can be regulated by environmental factors, such as, natural sunlight, salt water bathing, ultraviolet A irradiation and certain pathologies (psoriatic) (Nissen, et al., 1999, Slominski, et al., 2011). Previous studies reveled that approximately 80-90% of the CpG dinucleotides occurring in the *Penk* gene are concentrated at the 5' and 3' ends, with a nonrandom distribution (McClelland and Ivarie, 1982), and some CpG sites have been shown, by analysis of genomic DNA, to be methylated in a tissue specific fashion suggesting a control of the gene expression (Comb and Goodman, 1990). DNA methylation may also control the level of *Penk* expression since the methylation of CpG dinucleotides within the promoter inhibits its expression. In addition, that methylation affects a site located within a binding site for the AP-2 transcription factor. Thus, the methylation inhibits *Penk* expression by inhibition of AP-2 binding site (Comb and Goodman, 1990).

The studies of histone methylation have demonstrated the regulation of *Penk* expression by repressive marks, such as the methylation of H3K9me2 in upstream regions of the gene, typically enriched at peri-centromeric heterochromatin and sites of repressed chromatin; and by activating marks such as the methylation of H3K4me3 across the *Penk* promoter (Tomasiewicz, et al., 2012). This suggests that the distinct epigenetic profiles during the different cellular periods may allow the *Penk* to respond differentially to similar environmental cues.

At the miRNA level, it has been suggested an interaction between *Penk* and miR-29c (Slominski, et al., 2011), but there is too little information on this topic in current studies. (Table 2)

Prodynorfhin gene (*PDYN*)

PDYN is the precursor for the next opioid peptides 3 leu-enkephalin sequences, and other bigger peptides such as alpha- and beta-neoendorphins, dynorphin A and dynorphin B, which act as endogenous ligands for the Oprk1 (Levran, et al., 2012). Dynorphin peptides reduce basal and drug-induced dopamine levels in different areas of the dopaminergic, nigrostriatal, and mesolimbic, mesocortical systems. Expression of *Pdyn* is increased by cocaine behavior in anxiety tests demonstrating the anxiogenic role of prodynorphin-derived peptides (Wittmann, et al., 2009) Pdyn contains four exons: exon 1 and 2 encode the 5'UTR, exon 3 encodes a signal peptide, and exon 4 encodes the dynorphin peptides and has multiple transcription start sites located in exons 1 and 4 and introns 1 and 2 (Nikoshkov, et al., 2005, Tejeda, et al., 2012). It has been identified some alternatively spliced Pdyn transcripts, which contribute to dynorphin/ Oprk1 system diversity (Kimura, et al., 2006). Several potential transcription factor binding sites within the *Pdyn* promoter have been reported to play a role in regulating *Pdyn* expression. A polymorphic 68-bp tandem repeat polymorphism (rs35286281) that contains a putative AP-1, a site at −156 in the proximal promoter; and −2745 microsatellite (Babbitt, et al., 2010), and a calcium sensitive transcription repressor DREAM (downstream regulatory element antagonist modulator) that binds to the regulatory element (DRE) locate in the 5' UTR within exon 1 (Yuferov, et al., 2011).

Epigenetic factors, mainly DNA methylation, play an important but still unknown role in modulation of *Pdyn* expression. It has been analyzed the DNA methylation patterns of three CpG-rich regions of the *Pdyn*, a CpG island, cluster A in the proximal promoter and cluster B in coding exon 4 (Yuferov, et al., 2011). Those results have suggested that the CpG island is

implicated in tissue- or cell-specific regulation of gene expression, while the CpG cluster A may be associated to regulation of basal activity of the *Pdyn* (Yuferov, et al., 2011). In addition, the decrease in association of the methyl DNA binding protein MeCP2; to the promoter of *Pdyn* suggests the possibility that alterations in DNA methylation may be concomitant with altered *Pdyn* transcription (Reed, et al., 2012).

To study the chromatin modifications of the *Pdyn*, human neuroblastoma SH-SY5Y cells model is used by several groups, which is endogenously expressing the opioid system genes. It is shown that there is a relationship between chromatin modifications and Pdyn expression, thus epigenetic changes may precede gene transcription (D'Addario, et al., 2011). It has been demonstrated that there is an increase in H3K27me3 and a decrease in H3K4me3 and H3K9Ac in promoter when the gene expression is repressed (D'Addario, et al., 2011). In contrast, there is an increase in H3K4me3 and H3K9Ac together with a return on unmethylated H3K27me3 when the *Pdyn* expression back to normal levels after the original repression (D'Addario, et al., 2013). This hypothesis is also supported in the same study by temporal changes in RNA polymerase II (RNAPII) recruitment and activation consistent with epigenetic changes (D'Addario, et al., 2013).

On the other hand, a gene encoding a long non-coding RNA, AK090681, is transcribed from the opposite strand of *Pdyn*, and both are separate but overlapping transcription units. Some studies show that this gene appears to be actively transcribed in human embryonic stem cells while *Pdyn* does not. Interestingly, the promoter of AK090681 contains a CpG island which methylation status may correlate with that of H3K27, suggesting also an epigenetic regulation(Tejeda, et al., 2012). (Table 2)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

361 # Pronociceptin gene (*PNOC*)

362 PNOC is a precursor for 3 peptides, 1 nociceptin/orphanin FQ copy, 1 nocistatin copy and one 363 prepronociceptin copy and it is the endogenous agonist of the NOP, another opioid receptor 364 type in terms of primary structure, but without an in vitro opioid pharmacological profile 365 (Mollereau, et al., 1996). The overall structure and organization of the *Pnoc* codifying gen is 366 highly homolog of those codifying *Pomc*, *Pdyn* and *Penk*, it suggest a common evolutionary 367 ancestor. Consists in four exons, exon 1 constitutes the majority of the 5'UTR, exon two 368 contains the translational start site and the signal peptide, exon 3 contains the coding region 369 for the multiple bioactive peptides and exon 4 encodes the 3'UTR and poliadenylation signal. 370 The promoter region upstream of exon 1 contains several regulatory sites including cAMP 371 response elements and glucocorticoid receptor binding sites (Xie, et al., 1999, Arjomand and 372 Evans, 2001), while other study shows the presence of NFκB-binding site too (Wiggins, et al., 373 2010). Some reports show a pattern of splicing variants: in the 3'-end of exon 3, which result in 374 elongated and conserved C-terminal of the precursor protein, and other 2 spliced variants in 375 the exon 2 (Arjomand and Evans, 2001). This gene is a modulator of pain sensation and it is 376 essentially expressed in nerve tissues, brain and spinal cord, where its distribution correlates 377 with the localization of *Orl1* transcripts (Nothacker, et al., 1996).

378 There are few results about epigenetic regulation in Pnoc gene. A very recent study has 379 demonstrated a consistent increase in DNA methylation in the Pnoc promoter, suggesting that 380 epigenetic regulation might affect its expression level upon environmental changes such as 381 diet manipulation (Di Bonaventura MV, Pucci M, Maccarrone M, Cuomo V, Ciccocioppo R, 382 Gaetani S, Cifani C, d'Addario C, 2013).

383 Selective epigenetic changes in histone modifications, similar to *Pdyn*, are reported for the 384 *Pnoc* gene. It seems to be an inverse relationship between the repressive mark H3K27me3 and 385 the activating mark H3K9Ac, in the *Pnoc* promoter (D'Addario, et al., 2013). This fact has

suggested that there is a long-term maintenance of epigenetic chromatin state, which determines accessibility for transcription factors, and that might be still present even when the histone modifications are decreasing (D'Addario, et al., 2013). It confirms that, at least for the *Pnoc* gene, there is a transient genomic memory triggered by histone modifications occurring immediately at exposure.

There is no evidence of epigenetic control at miRNA level in this gene. Therefore this is a field to focus future studies. (Table2)

Table 2: The epigenetic mechanisems involved in the Opioid Protein Precursors gene expression

Conclusion

Different physiological functions have been reported for the opioid system. Discovering and validating the complete biological roles of these three genes will require extensive studies of each in multiple physiological and pharmacological contexts and, in particular, studies that define with more precision their transcriptional and posttranscriptional regulation. In this context the opioid receptors show an epigenetic regulation. DNA methylation is confirmed in the case of *Oprm1, Oprd1 and Oprl1*, while the chromatin remodeling is reported in four of the receptors. Although four promoters have similarity between them, they use different epigenetic regulation forms and they exhibit different pattern of expression during the cell differentiation. Moreover, the opioid peptide precursors are also epigenetically regulated. DNA methylation is confirmed in four of them, being important for gene expression and tissue specificity. Histone methylation is also present in four precursors, which suggest the possible genomic memory adquisition at least in Pnoc.

In spite of thet, these genes interact with environment factors that are increasingly recognized to be complicated by intertwined biological processes, including temporal and spatial controls that must underlie the activity of any drug receptor in the whole organism. Consequently, future studies of opioid system genes must go beyond the action of transcription factors to include factors affecting their epigenetic states, physiological contexts, and posttranscriptional control to develop individualized prompt prevention and treatment strategies

Abbreviations

Ors: Opioid receptors

MOR: mu opioid receptor protein

DOR: delta opioid receptor protein

KOR: kappa opioid receptor protein

NOP: nociceptin receptor protein

Oprm1: mu opioid receptor gen

Oprd1: delta opioid receptor gen

Oprk1: kappa opioid receptor gen

Oprl1: nociceptin receptor protein

POMC: proopiomelanocortin protein

PENK: proenkephalin protein

PDYN: prodynorphin protein

PNOC: nociceptin/orphanin FQ protein

Pomc: proopiomelanocortin gen

Penk: proenkephalin gen

Pdyn: prodynorphin gen

Pnoc: nociceptin/orphanin FQ gen

Sox2: (Sry-like high-mobility-group box gene

Sp1: specificity protein 1

iGA: Sp1 on an inverted GA motif

PCBP: poly C binding protein

CREB: cyclic adenosine monophosphate response element binding protein

Oct-1: octamer-1

PU.1: PU box binding on a 34-bp silencer region

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

450 PARP1: polyADP-ribose polymerase 1 on a double-stranded poly-C sequence

451 Sp3: transcription factor binding to the 5' UTR specificity protein 3

452 REST: repressor element-1 silencing transcription factor

453 MeCP2: methyl CpG binding protein 2

454 RA: retinoic acid

455 Ets-1: E-twenty six 1

456 USF: upstream stimulatori factor

457 MBD2: methyl-CpG binding domain protein 2

458 PI3K: fosfatidilinositol 3-kinase

459 NGF: nerve growth factor

460 AP2: activating protein

461 IK: Ikaros

462 nGRE: one inhibiting transcription factor binding site

463 Hdac2: histone deacetylase 2

464 Dnmt1: (cytosine-5)-methyltransferase 1

465 MAP2K8: mitogen activated protein kinase 2

466 PC1: proprotein convertase 1

467 PC2: proprotein convertase 2

468 NAc: nucleus accumbens

469 DREAM: downstream regulatory element antagonist modulator

470 *Orl1:* opioid receptor-like receptor

471 BDNF: brain-derived neurotrophic factor

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

472 # Acknowledgements

473 We would like to thank to Basque Government and Merck Serono for supporting this work.
474 Iraia Muñoa and Itziar Urizar were supported by fellowship from Basque Government and
475 UPV/EHU respectively. The funders had no role in study design, data collection and analysis,
476 decision to publish, or preparation of the manuscript.

477 # Conflict of interest

478 The authors have no conflicts of interest to declare.

479 # Author's contribution

480 I.M, and I.U. wrote the manuscript, L.C. and J.I. provided conceptual support and N.S. wrote
481 and supervise the manuscript.

References

Arjomand J, Evans CJ. 2001. Differential splicing of transcripts encoding the orphanin FQ/nociceptin precursor. J Neurochem 77:720-729.

Babbitt CC, Silverman JS, Haygood R, Reininga JM, Rockman MV, Wray GA. 2010. Multiple Functional Variants in cis Modulate PDYN Expression. Mol Biol Evol 27:465-479.

Bekdash RA. 2012. PhD proyect. Epigenetic effects of fetal alcohol exposure on hypothalamic proopiomelanocortin gene

Bi J, Hu X, Loh HH, Wei LN. 2001. Regulation of mouse kappa opioid receptor gene expression by retinoids. J Neurosci 21:1590-1599.

Bodnar RJ. 2007. Endogenous opiates and behavior: 2006. Peptides 28:2435-2513.

Bruchas MR, Land BB, Chavkin C. 2010. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res 1314:44-55.

Caputi FF, Di Benedetto M, Carretta D, Bastias del Carmen Candia S, D'Addario C, Cavina C, Candeletti S, Romualdi P. 2014. Dynorphin/KOP and nociceptin/NOP gene expression and epigenetic changes by cocaine in rat striatum and nucleus accumbens. Prog Neuropsychopharmacol Biol Psychiatry 49:36-46.

Chen HC, Wei LN, Loh HH. 1999. Expression of mu-, kappa- and delta-opioid receptors in P19 mouse embryonal carcinoma cells. Neuroscience 92:1143-1155.

Chen YL, Law PY, Loh HH. 2008. NGF/PI3K signaling-mediated epigenetic regulation of delta opioid receptor gene expression. Biochem Biophys Res Commun 368:755-760.

Comb M, Goodman HM. 1990. CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Res 18:3975-3982.

D'Addario C, Caputi FF, Ekstrom TJ, Di Benedetto M, Maccarrone M, Romualdi P, Candeletti S. 2013. Ethanol induces epigenetic modulation of prodynorphin and pronociceptin gene expression in the rat amygdala complex. J Mol Neurosci 49:312-319.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

507 D'Addario C, Johansson S, Candeletti S, Romualdi P, Ogren SO, Terenius L, Ekstrom TJ. 2011.
508 Ethanol and acetaldehyde exposure induces specific epigenetic modifications in the
509 prodynorphin gene promoter in a human neuroblastoma cell line. FASEB J 25:1069-1075.

510 Di Bonaventura MV, Pucci M, Maccarrone M, Cuomo V, Ciccocioppo R, Gaetani S, Cifani C,
511 d'Addario C. 2013. Resistance to diet-induced obesity is associated to selective epigenetic
512 regulation of hypothalamic neuropeptides gene expression. 36" CONGRESSO NAZIONALE DELLA
513 SOCIETA ITALIANA DI FARMACOLOGIA

514 Fichna J, Janecka A, Costentin J, Do Rego JC. 2007. The endomorphin system and its evolving
515 neurophysiological role. Pharmacol Rev 59:88-123.

516 Gardiner-Garden M, Frommer M. 1994. Transcripts and CpG islands associated with the pro-
517 opiomelanocortin gene and other neurally expressed genes. J Mol Endocrinol 12:365-382.

518 Goumon Y, Lugardon K, Gadroy P, Strub JM, Welters ID, Stefano GB, Aunis D, Metz-Boutigue MH.
519 2000. Processing of proenkephalin-A in bovine chromaffin cells. Identification of natural derived
520 fragments by N-terminal sequencing and matrix-assisted laser desorption ionization-time of flight
521 mass spectrometry. J Biol Chem 275:38355-38362.

522 He Y, Yang C, Kirkmire CM, Wang ZJ. 2010. Regulation of opioid tolerance by let-7 family
523 microRNA targeting the mu opioid receptor. J Neurosci 30:10251-10258.

524 Hu X, Bi J, Loh HH, Wei LN. 2002. Regulation of mouse kappa opioid receptor gene expression by
525 different 3'-untranslated regions and the effect of retinoic acid. Mol Pharmacol 62:881-887.

526 Hwang CK, Kim CS, Kim do K, Law PY, Wei LN, Loh HH. 2010. Up-regulation of the mu-opioid
527 receptor gene is mediated through chromatin remodeling and transcriptional factors in
528 differentiated neuronal cells. Mol Pharmacol 78:58-68.

529 Hwang CK, Song KY, Kim CS, Choi HS, Guo XH, Law PY, Wei LN, Loh HH. 2009. Epigenetic
530 programming of mu-opioid receptor gene in mouse brain is regulated by MeCP2 and Brg1
531 chromatin remodelling factor. J Cell Mol Med 13:3591-3615.

532 Hwang CK, Wagley Y, Law PY, Wei LN, Loh HH. 2012. MicroRNAs in opioid pharmacology. J
533 Neuroimmune Pharmacol 7:808-819.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

534 Kieffer BL, Gaveriaux-Ruff C. 2002. Exploring the opioid system by gene knockout. Prog
535 Neurobiol 66:285-306.

536 Kimura K, Wakamatsu A, Suzuki Y, Ota T, Nishikawa T, Yamashita R, Yamamoto J, Sekine M,
537 Tsuritani K, Wakaguri H, Ishii S, Sugiyama T, Saito K, Isono Y, Irie R, Kushida N, Yoneyama T,
538 Otsuka R, Kanda K, Yokoi T, Kondo H, Wagatsuma M, Murakawa K, Ishida S, Ishibashi T,
539 Takahashi-Fujii A, Tanase T, Nagai K, Kikuchi H, Nakai K, Isogai T, Sugano S. 2006. Diversification
540 of transcriptional modulation: large-scale identification and characterization of putative
541 alternative promoters of human genes. Genome Res 16:55-65.

542 Knoll AT, Carlezon WA,Jr. 2010. Dynorphin, stress, and depression. Brain Res 1314:56-73.

543 Koneru A, Satyanarayana S and Rizwan S. 2009. Endogenous opioids: their physiological role
544 and receptors. Global Journal of Pharmacology 3(3):149-153

545 Kreek MJ, LaForge KS, Butelman E. 2002. Pharmacotherapy of addictions. Nat Rev Drug Discov
546 1:710-726.

547 LaForge KS, Yuferov V, Kreek MJ. 2000. Opioid receptor and peptide gene polymorphisms:
548 potential implications for addictions. Eur J Pharmacol 410:249-268.

549 Lavender P, Clark AJ, Besser GM, Rees LH. 1991. Variable methylation of the 5'-flanking DNA of
550 the human pro-opiomelanocortin gene. J Mol Endocrinol 6:53-61.

551 Law PY, Loh HH, Wei LN. 2004. Insights into the receptor transcription and signaling:
552 implications in opioid tolerance and dependence. Neuropharmacology 47 Suppl 1:300-311.

553 Levran O, Yuferov V, Kreek MJ. 2012. The genetics of the opioid system and specific drug
554 addictions. Hum Genet 131:823-842.

555 Lin YC, Flock KE, Cook RJ, Hunkele AJ, Loh HH, Ko JL. 2008. Effects of trichostatin A on neuronal
556 mu-opioid receptor gene expression. Brain Res 1246:1-10.

557 Lu S, Loh HH, Wei LN. 1997. Studies of dual promoters of mouse kappa-opioid receptor gene.
558 Mol Pharmacol 52:415-420.

559 McClelland M, Ivarie R. 1982. Asymmetrical distribution of CpG in an 'average' mammalian
560 gene. Nucleic Acids Res 10:7865-7877.

Mollereau C, Parmentier M, Mailleux P, Butour JL, Moisand C, Chalon P, Caput D, Vassart G, Meunier JC. 1994. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 341:33-38.

Mollereau C, Simons MJ, Soularue P, Liners F, Vassart G, Meunier JC, Parmentier M. 1996. Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene. Proc Natl Acad Sci U S A 93:8666-8670.

Neer EJ. 1995. Heterotrimeric G proteins: organizers of transmembrane signals. Cell 80:249-257.

Nikoshkov A, Hurd YL, Yakovleva T, Bazov I, Marinova Z, Cebers G, Pasikova N, Gharibyan A, Terenius L, Bakalkin G. 2005. Prodynorphin transcripts and proteins differentially expressed and regulated in the adult human brain. FASEB J 19:1543-1545.

Nissen JB, Avrach WW, Hansen ES, Stengaard-Pedersen K, Kragballe K. 1999. Decrease in enkephalin levels in psoriatic lesions after calcipotriol and mometasone furoate treatment. Dermatology 198:11-17.

Nothacker HP, Reinscheid RK, Mansour A, Henningsen RA, Ardati A, Monsma FJ,Jr, Watson SJ, Civelli O. 1996. Primary structure and tissue distribution of the orphanin FQ precursor. Proc Natl Acad Sci U S A 93:8677-8682.

O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ. 2002. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl) 160:19-29.

Park SW, He Y, Ha SG, Loh HH, Wei LN. 2008. Epigenetic regulation of kappa opioid receptor gene in neuronal differentiation. Neuroscience 151:1034-1041.

Park SW, Huq MD, Loh HH, Wei LN. 2005. Retinoic acid-induced chromatin remodeling of mouse kappa opioid receptor gene. J Neurosci 25:3350-3357.

Plagemann A, Harder T, Brunn M, Harder A, Roepke K, Wittrock-Staar M, Ziska T, Schellong K, Rodekamp E, Melchior K, Dudenhausen JW. 2009. Hypothalamic proopiomelanocortin promoter methylation becomes altered by early overfeeding: an epigenetic model of obesity and the metabolic syndrome. J Physiol 587:4963-4976.

Reed B, Fang N, Mayer-Blackwell B, Chen S, Yuferov V, Zhou Y, Kreek MJ. 2012. Chromatin alterations in response to forced swimming underlie increased prodynorphin transcription. Neuroscience 220:109-118.

Schneeberger M, Altirriba J, Garcia A, Esteban Y, Castano C, Garcia-Lavandeira M, Alvarez CV, Gomis R, Claret M. 2012. Deletion of miRNA processing enzyme Dicer in POMC-expressing cells leads to pituitary dysfunction, neurodegeneration and development of obesity. Mol Metab 2:74-85.

Slominski AT, Zmijewski MA, Zbytek B, Brozyna AA, Granese J, Pisarchik A, Szczesniewski A, Tobin DJ. 2011. Regulated proenkephalin expression in human skin and cultured skin cells. J Invest Dermatol 131:613-622.

Song KY, Choi HS, Hwang CK, Kim CS, Law PY, Wei LN, Loh HH. 2009. Differential use of an in-frame translation initiation codon regulates human mu opioid receptor (OPRM1). Cell Mol Life Sci 66:2933-2942.

Stevens A, Begum G, Cook A, Connor K, Rumball C, Oliver M, Challis J, Bloomfield F, White A. 2010. Epigenetic changes in the hypothalamic proopiomelanocortin and glucocorticoid receptor genes in the ovine fetus after periconceptional undernutrition. Endocrinology 151:3652-3664.

Subiran N, Casis L, Irazusta J. 2011. Regulation of male fertility by the opioid system. Mol Med 17:846-853.

Tejeda HA, Shippenberg TS, Henriksson R. 2012. The dynorphin/kappa-opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci 69:857-896.

Tomasiewicz HC, Jacobs MM, Wilkinson MB, Wilson SP, Nestler EJ, Hurd YL. 2012. Proenkephalin mediates the enduring effects of adolescent cannabis exposure associated with adult opiate vulnerability. Biol Psychiatry 72:803-810.

Tseung LF. 1995. The pharmacology of opioid peptides / edited by Leon F. Tseng. xiii, 524 p. : ill.

Wang G, Liu T, Wei LN, Law PY, Loh HH. 2005. DNA methylation-related chromatin modification in the regulation of mouse delta-opioid receptor gene. Mol Pharmacol 67:2032-2039.

Wang G, Wei LN, Loh HH. 2003. Transcriptional regulation of mouse delta-opioid receptor gene by CpG methylation: involvement of Sp3 and a methyl-CpG-binding protein, MBD2, in transcriptional repression of mouse delta-opioid receptor gene in Neuro2A cells. J Biol Chem 278:40550-40556.

Wei LN, Loh HH. 2011. Transcriptional and epigenetic regulation of opioid receptor genes: present and future. Annu Rev Pharmacol Toxicol 51:75-97.

Wei LN, Loh HH. 2002. Regulation of opioid receptor expression. Curr Opin Pharmacol 2:69-75.

Wick MJ, Minnerath SR, Roy S, Ramakrishnan S, Loh HH. 1995. Expression of alternate forms of brain opioid 'orphan' receptor mRNA in activated human peripheral blood lymphocytes and lymphocytic cell lines. Brain Res Mol Brain Res 32:342-347.

Wiggins JE, Patel SR, Shedden KA, Goyal M, Wharram BL, Martini S, Kretzler M, Wiggins RC. 2010. NFkappaB promotes inflammation, coagulation, and fibrosis in the aging glomerulus. J Am Soc Nephrol 21:587-597.

Wittmann W, Schunk E, Rosskothen I, Gaburro S, Singewald N, Herzog H, Schwarzer C. 2009. Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacology 34:775-785.

Wu Y. 2012. Sustained epigenetic programming of POMC by early life stress.

Wu Q, Hwang CK, Zheng H, Wagley Y, Lin HY, Kim do K, Law PY, Loh HH, Wei LN. 2013. MicroRNA 339 down-regulates mu-opioid receptor at the post-transcriptional level in response to opioid treatment. FASEB J 27:522-535.

Xie GX, Ito E, Maruyama K, Suzuki Y, Sugano S, Sharma M, Pietruck C, Palmer PP. 1999. The promoter region of human prepro-nociceptin gene and its regulation by cyclic AMP and steroid hormones. Gene 238:427-436.

Yuferov V, Nielsen DA, Levran O, Randesi M, Hamon S, Ho A, Morgello S, Kreek MJ. 2011. Tissue-specific DNA methylation of the human prodynorphin gene in post-mortem brain tissues and PBMCs. Pharmacogenet Genomics 21:185-196.

Zhang H, Wang F, Kranzler HR, Zhao H, Gelernter J. 2013a. Profiling of childhood adversity-associated DNA methylation changes in alcoholic patients and healthy controls. PLoS One 8:e65648.

Zhang N, Lin JK, Chen J, Liu XF, Liu JL, Luo HS, Li YQ, Cui S. 2013b. MicroRNA 375 mediates the signaling pathway of corticotropin-releasing factor (CRF) regulating pro-opiomelanocortin (POMC) expression by targeting mitogen-activated protein kinase 8. J Biol Chem 288:10361-10373.

Table 1

	OPRM1	OPRD1	OPRK1	OPRL1
Silencing				
Regulatory elements	Oct1, PU.1, PARP1, Sp3, REST	Sp3, IK	IK	-
Metilation Mechanisems	Metilation ↑ MeCp2	Metilation ↑ MeCP2	-	-
Histon modifications	-	Histone deacetilases H3, H4	H3K9 me2	-
MiroRNA	miR-23b, miR-339, Let-7	-	-	-
Activation				
Regulatory elements	Sox2, Sp1, iGA, PCBP, CREB,	STAT6, Sp1, Ets-1, USF, NF-kB, AP2	c.Myc, Sp1, AP2	
Metilation Mechanisems	Hipometilation ↓ MeCp2	Hipometilation ↓ MeCp2	-	Hipometilation
Histon modifications	Histone acetilases H3, H4	Demetilation of H3K9me3 by NGF/PI3K signalling	H3K4 me2	-
MiroRNA	-	-	-	-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 2

	POMC	PENK	PDYN	PNOC
Silencing				
Regulatory elements	nGRE	-	DREAM	-
Metilation Mechanisems	Metilation ↑MeCp2	Metilation ↑MeCp2	Metilation ↑MeCp2	Metilation
Histon modifications		H3K9 me2	H3K27me3	H3K27me3
MiroRNA	miR-375	miR-29c	-	-
Activation				
Regulatory elements	FoxO1, STAT3 Sp1, NF-kB	AP2, Sp1, CREB	AP1	CREB, NF-kB
Metilation Mechanisems	Hipometilation		H3K4me3, H3K9ac	H3K9ac
Histon modifications	H3K9ac	H3K4 me3	-	-
MiroRNA	-	-	-	-